Építés alatt – nem éles oldal
Belépés
Befejeződött2. fázis

A phase-2, multi-centre, prospective, randomized, standard-of-care plus placebo-controlled, patient and central evaluator blinded, parallel arm, clinical study to evaluate safety, tolerability and efficacy of the recommended phase-2 dose of AUP1602-C in two dosing frequencies as a topical treatment for non-healing neuro-ischemic diabetic foot ulcers

A legfontosabb adatok

Ki végzi
Aurealis Oy
Hol
Lengyelország, Németország és Olaszország9 helyszín, 3 országbanVálassz országot a helyszínekhez
Állapot
Befejeződött
Fázis
2. fázis
Résztvevők
100 fő vett részt
Kezdés
2023. júl. 21.
Befejezés
2025. okt. 9.
A vizsgálat típusa
Beavatkozással járó
A regiszteradat frissítve
2025. október 9.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 44 feltétel megnézéseKevesebb

Ki vehet részt

  • Male or female patients aged 18 years and above, depending on the Investigator’s assessment of physical and psychological wellbeing of the patient to comply with study procedures and follow-up
  • Females of childbearing potential must agree to use a highly effective contraceptive measure (methods that can achieve a failure rate of less than 1% per year when used consistently and correctly) , throughout the study. / Male patients who are biologically capable of having children must agree to apply at least two methods of contraception including male barrier protection throughout the study
  • Patients who understand and are willing to comply with study procedures and give written informed consent prior to enrolment in the study or initiation of study procedures
  • Patients with diabetes mellitus (DM) of type 1 or 2 having a glycosylated haemoglobin (HbA1c) of ≤ 11.0% OR 97.0 mmol/mol OR 14.9 mmol/l at randomization (results up to 3 months prior to signing ICF accepted) undergoing therapy for glycaemic control using available diabetes drugs including insulin
  • Patients with at least one DFU that fulfils all of the following criteria: •Non-healing target ulcer defined as ≤ 20.0 % reduction in area in response to SoC during the 2-weeks run-in period, • Duration: ≥4 weeks and ≤12 months at screening visit 1, • Located either in the plantar or on the dorsum of foot, or at or below the ankle, • Ulcer is accessible for administration of IMP and can be completely covered by the primary and secondary dressings, • Full-thickness, not involving bone or joints (i.e., University of Texas classification Grade 1A, 1C, 2A, 2C)(5) • No clinical signs of active wound infection defined by IDSA/IWGDF criteria(6) or clinical evidence osteomyelitis at randomization (V1), • Area of the target ulcer between 1.0-10.0 cm2 after debridement at randomization (V1), • Ulcer and periwound tissue suitable for application of semipermeable film dressings (i.e., no contraindications and sufficient periwound space to hold the dressing)
  • Patients with more than one ulcer will be included if ulcers are separated by a minimum of 2.0 cm healthy tissue. The largest ulcer fulfilling inclusion criteria will be selected for the investigational treatment
  • Patients with either an ankle brachial index (ABI) ≥ 0.7 OR a toe-brachial index (TBI) ≥ 0.5, AND a toe systolic pressure of at least 50.0 mmHg (or ankle systolic pressure of at least 70.0 mmHg if toe-pressure is not measured) on the foot with the target ulcer
  • Revascularized patients with an ulcer fulfilling the inclusion criteria can be included 3.0 months after the procedure
  • Patients with an assessment of the baseline level of neuropathy in the lower limb where the target ulcer is located
  • Patients must be willing to wear off-loading footwear, while ambulating, for the period requested by the Investigator
  • A woman of childbearing potential (WOCBP) must have a negative serum pregnancy test at the time of screening after sign the informed consent and a negative pregnancy dip-stick test at baseline (before starting treatment)

Ki nem vehet részt

  • Current or previous (within 2 weeks prior to start of run-in period) treatment with another investigational drug and/or medical device or participation in another clinical study
  • Target ulcers requiring urgent vascular surgical interventions
  • Prior radiation therapy (within 6 weeks prior to first IMP (AUP1602-C or placebo) dosing) of any part of the foot/leg bearing the target ulcer under study or total body irradiation
  • Patients receiving haemodialysis or continuous ambulatory peritoneal dialysis (CAPD) therapy
  • Positive for hepatitis B or C virus (HBV, HCV), or human immunodeficiency virus (HIV) (serology test results up to 3 months prior signing ICF accepted)
  • Patients with confirmed active infection with SARS-CoV-2 and related disease (COVID-19) at Baseline (V1) prior to first administration of trial medication
  • Planned major surgery during the run-in, treatment and post-treatment efficacy and safety follow-up period of the study
  • Known abuse of alcohol, drugs, or medical products. Tobacco use will be allowed
  • Previous treatment with AUP1602-C
  • Myocardial infarction diagnosed within 1 month prior to start of run-in period
  • Current or previous (within 1 week prior to first IMP (AUP1602-C or placebo) dosing) treatment with active wound care agents (e.g., local/topical antibiotics OR antibacterials such as silver, iodine, chlorhexidine) OR systemic antibiotics for any indication
  • Pregnant or lactating woman at the time of signing the informed consent and prior to first IMP (AUP1602-C or placebo) dosing
  • Current or previous (within 2 weeks prior to first IMP (AUP1602-C or placebo dosing) use of corticosteroids and immunosuppressants. Treatment with immunosuppressive agents with known therapeutic effects longer than 2 weeks may be considered as exclusion and should be consulted with Medical Monitor/Sponsor
  • Target ulcer with known or suspected active infection, which requires antimicrobials. Any antibiotic therapy must be completed or discontinued within 1 week prior to first IMP (AUP1602-C or placebo) dosing
  • Target ulcer other than non-healing DFU fulfilling inclusion criteria (e.g., including, but not limited to, pressure ulcers, burn wounds)
  • Sickle-cell diseases, Reynaud’s, or other peripheral vascular disease including venous leg ulcers or any vasculitic ulcer irrespective of the cause will be excluded
  • Patients with other reasons for wound healing disturbances: e.g., bleeding disorders, vitamin K deficiency, hypocalcaemia, major immune deficiencies
  • Active malignant disease of any kind except for basal cell carcinoma (of the skin) not co-located with the target ulcer. A patient, who has had a malignant disease in the past, completed treatment and is currently disease-free and not on active treatment for at least 3 months, may be considered for study entry. Cancer therapies with known therapeutic effects longer than 3 months may be considered as exclusion and should be consulted with Medical Monitor/Sponsor
  • Any diagnosed unstable psychological or physical condition including major organ failure that could interfere with compliance
  • Known hypersensitivity to any of the components of AUP1602-C or placebo
  • Ulcer of University of Texas Grade ≥3, with deep abscess, sinus track, necrosis or gangrene that cannot be removed by debridement
  • Serum creatinine level of >3.0 times the upper limit of normal (ULN)
  • Haemoglobin of less than 8.5 g/dL
  • Liver transaminase & total bilirubin levels greater than 3 times ULN
  • Current or previous (within 30 days prior to start of run-in period) treatment of target ulcer with a treatment that could interfere with wound healing/IMP such as biological agents, growth factors, skin equivalents/substitutes (e.g., Regranex®, Apligraf®, or Dermagraft®), keratinocytes, platelet-rich-plasma, collagen products, blood products, placental products, oxygen therapy, topical steroids
  • White Blood Cells (WBC) < 3.0 x 109 cells/L; > 12.0 x 109 cells/L
  • Albumin < 2.5 g/dL (or total protein < 4.0 g/dl)
  • Active or unstable Charcot deformity of the study foot (i.e., foot is erythematous, warm, oedematous, and is actively remodelling)
  • The patient has any other factor/reason which may, in the opinion of the Investigator, compromise participation and/or follow-up in the study
  • Close affiliation with the Investigator (e.g., a close relative, financially dependent on the investigational site) or patient who is an employee of the Sponsor’s company
  • Patients who are institutionalized because of legal or regulatory order
  • Target ulcers with excessive exudation requiring more than one dressing change within 24-hrs
  • Target ulcers with clinically significant periwound skin maceration

Hol van ez a vizsgálat?

3 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

To investigate local and systemic safety and tolerability of the recommended Phase 2 Dose (RP2D) (2.5 x 108 CFU/cm2 ulcer size) and selected treatment schedules of AUP1602-C and of the placebo control arm, in patients with DFU fulfilling inclusion criteria.

A teljes eredeti leírásKevesebb

To evaluate the proportion of patients achieving total wound closure with the 2 dosing frequencies of AUP1602-C and placebo treatment.

Adatok és források

Regiszteradat
Szerepel az EU hivatalos vizsgálati nyilvántartásában (CTIS).
A regiszteradat frissítve
2025. október 9.